Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 270,194,816
  • Shares Outstanding, K 6,830,000
  • Annual Sales, $ 67,325 M
  • Annual Income, $ 12,808 M
  • 60-Month Beta 0.43
  • Price/Sales N/A
  • Price/Cash Flow 12.30
  • Price/Book 7.73
Trade RHHBY with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/01/24
  • Annual Dividend & Yield 0.85 (2.14%)
  • Most Recent Dividend 0.847 on 03/14/24
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 1.46
  • Number of Estimates 1
  • High Estimate 1.46
  • Low Estimate 1.46
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.7600 +20.73%
on 07/08/24
40.8000 -0.10%
on 07/26/24
+6.1000 (+17.60%)
since 06/26/24
3-Month
29.2000 +39.59%
on 05/02/24
40.8000 -0.10%
on 07/26/24
+10.5100 (+34.74%)
since 04/26/24
52-Week
29.2000 +39.59%
on 05/02/24
40.8000 -0.10%
on 07/26/24
+1.6100 (+4.11%)
since 07/26/23

Most Recent Stories

More News
Why Weight Loss Drug Developer Stocks Tumbled on Thursday

Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.

VKTX : 65.98 (+2.01%)
RHHBY : 40.7600 (+3.03%)
NVO : 126.73 (-0.88%)
LLY : 804.62 (-2.02%)
Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch?

Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.

NVO : 126.73 (-0.88%)
LLY : 804.62 (-2.02%)
RHHBY : 40.7600 (+3.03%)
This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It?

This company hasn't made its debut on the weight-loss market yet, but it may.

LLY : 804.62 (-2.02%)
RHHBY : 40.7600 (+3.03%)
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche

Neither is a leader right now, but one of them might be on track to change that.

LLY : 804.62 (-2.02%)
PFE : 30.77 (+3.39%)
RHHBY : 40.7600 (+3.03%)
Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped

Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock.

RHHBY : 40.7600 (+3.03%)
LLY : 804.62 (-2.02%)
NVO : 126.73 (-0.88%)
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the reintroduction of Susvimo ® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the...

RHHBY : 40.7600 (+3.03%)
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END

ONCY : 1.0400 (unch)
ONC.TO : 1.44 (+1.41%)
KYMR : 44.54 (+1.14%)
RHHBY : 40.7600 (+3.03%)
GILD : 77.01 (+0.65%)
AMGN : 334.85 (+0.16%)
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033

ONCY : 1.0400 (unch)
ONC.TO : 1.44 (+1.41%)
KYMR : 44.54 (+1.14%)
RHHBY : 40.7600 (+3.03%)
GILD : 77.01 (+0.65%)
AMGN : 334.85 (+0.16%)
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

/CNW/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may...

RHHBY : 40.7600 (+3.03%)
ONCY : 1.0400 (unch)
VSTM : 2.96 (-0.34%)
CADL : 6.70 (+2.92%)
FGEN : 1.1600 (-5.69%)
REGN : 1,078.63 (+1.36%)
ONC.TO : 1.44 (+1.41%)
The Fight Against Pancreatic Cancer: Biotech Firms Develop New Solutions for Rising Gen X Cases

USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may be experiencing larger per-capita...

ONCY : 1.0400 (unch)
ONC.TO : 1.44 (+1.41%)
RHHBY : 40.7600 (+3.03%)
VSTM : 2.96 (-0.34%)
CADL : 6.70 (+2.92%)
FGEN : 1.1600 (-5.69%)
REGN : 1,078.63 (+1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its...

See More

Key Turning Points

3rd Resistance Point 41.6800
2nd Resistance Point 41.2400
1st Resistance Point 41.0000
Last Price 40.7600
1st Support Level 40.3200
2nd Support Level 39.8800
3rd Support Level 39.6400

See More

52-Week High 40.8000
Last Price 40.7600
Fibonacci 61.8% 36.3688
Fibonacci 50% 35.0000
Fibonacci 38.2% 33.6312
52-Week Low 29.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar